

Understanding the impact of high-risk human papillomavirus on oropharyngeal squamous cell carcinomas in Taiwan: A retrospective cohort study

1
2 Guadalupe Lorenzatti Hiles^{1,2¶}, Kai-Ping Chang^{3,4¶*}, Emily L. Bellile⁵, Chun-I Wang⁶, Wei-
3 Chen Yen³, Christine M. Goudsmit^{1,2}, Hannah L. Briggs^{1,2}, Trey B. Thomas^{1,2,#a}, Lila Peters^{1,2},
4 Macy A. Afsari^{1,2}, Lisa M. Pinatti^{1,2,7,#b}, Anna C. Morris^{1,2,#c}, Nadine Jawad^{1,2,#d}, Thomas E.
5 Carey^{1,2&*}, Heather M. Walline^{1,2&*}.

6
7 ¹Division of Head and Neck Surgery, Department of Otolaryngology, University of Michigan
8 Medical School, Ann Arbor, Michigan, United States of America.

9
10 ²University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States of America.

11
12 ³Department of Otolaryngology-Head & Neck Surgery, Chang Gung Memorial Hospital (Linkou
13 Medical Center), Taoyuan, Taiwan, Republic of China.

14
15 ⁴College of Medicine, Chang Gung University, Taoyuan, Taiwan, Republic of China.

16
17 ⁵Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor,
18 Michigan, United States of America.

19
20 ⁶Radiation Biology Research Center, Institute for Radiological Research, Chang Gung
21 University and Chang Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China.

22
23 ⁷Cancer Biology Program, Rackham Graduate School, University of Michigan, Ann Arbor,
24 Michigan, United States of America.

25
26 ^{#a}Current address: School of Public Health, University of Michigan, Ann Arbor, Michigan,
27 United States of America.

28

29 ^{#b}Current address: Department of Molecular Pathology, Yale New Haven Health, New Haven,
30 Connecticut, United States of America.

31
32 ^{#c}Current address: Department of Health Policy and Management, Milken Institute School of
33 Public Health, George Washington University, Washington DC, United States of America.

34
35 ^{#d}Current address: Stanford University School of Medicine, Stanford, California, United States of
36 America.

37

38 *Corresponding authors:

39 E-mail: dr.kpchang@gmail.com (K-PC),

40 careyte@med.umich.edu (TEC),

41 hwalline@med.umich.edu (HMW)

42

43 [¶]These authors contributed equally to this work.

44 [&]These authors are joint senior authors and also contributed equally to this work.

45

46 **Short Title:**

47 High-risk HPV and OPSCC in Taiwan

48 **Abstract**

49 **Background and Objectives**

50 Human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC)
51 is increasing globally. In Taiwan, HPV-positive OPSCC is obscured by tobacco, alcohol, and
52 betel quid use. We investigated the role of high-risk HPV (hrHPV) in a large retrospective
53 Taiwan OPSCC cohort.

54

55 **Methods and Results**

56 The cohort of 541 OPSCCs treated at Chang Gung Memorial Hospital from 1998-2016
57 consisted of 507 men (94%) and 34 women (6%). Most used tobacco (81%), alcohol (51%), and
58 betel quid (65%). Formalin-fixed, paraffin-embedded tissue was used for p16 staining (a
59 surrogate marker for HPV) and testing for HPV DNA presence and type by Multiplex HPV
60 PCR-MassArray. HPV DNA and/or p16 staining (HPV-positive) was found in 28.4% (150/528)
61 tumors. p16 and HPV DNA were strongly correlated ($F < 0.0001$). HPV16 was present in
62 82.8%, and HPV58 in 7.5% of HPV-positive tumors. HPV was associated with higher age (55.5
63 vs. 52.7 years, $p = 0.004$), lower T-stage ($p = 0.008$) better overall survival (OS) (hazard ratio
64 [HR] 0.58 [95% CI 0.42-0.81], $p = 0.001$), and disease-free survival (DFS) (HR 0.54 [95% CI
65 0.40-0.73], $p < 0.0001$). Alcohol was strongly associated with recurrence and death (OS: HR
66 2.06 [95% CI 1.54-2.74], $p < 0.0001$; DFS: HR 1.72 [95% CI 1.33-2.24], $p < 0.0001$). OS and
67 DFS in HPV-positive cases decreased for alcohol users ($p < 0.0001$). Obscured by the strong
68 alcohol effect, predictive associations were not found for tobacco or betel quid.

69

70 **Conclusions**

71 As with HPV-positive OPSCC globally, HPV is an increasingly important etiological
72 factor in Taiwanese OPSCC. HPV-positive OPSCC has considerable survival benefit, but that is
73 reduced by alcohol, tobacco, and betel quid use. hrHPV is a cancer risk factor in males and
74 females. Vaccinating both sexes with a multivalent vaccine including HPV58, combined with
75 alcohol and tobacco cessation policies will be effective cancer-prevention public health strategies
76 in Taiwan.

77

78 **Introduction**

79 The occurrence of oropharyngeal squamous cell carcinoma (OPSCC) is rapidly
80 increasing in North America and Western Europe, accounting for approximately 100,000 new
81 cases worldwide each year [1-3]. In particular, the incidence of OPSCC has been dramatically
82 rising since 1973, at the point of surpassing 5% annual increment in the United States in 2000 [2,
83 4, 5]. OPSCC has been traditionally associated with tobacco use and excessive alcohol
84 consumption as primary risk factors [6-17]. However, recent behavioral changes in Western
85 countries have promoted a marked drop in the prevalence of these major risk factors [7, 13, 18,
86 19]. In contrast, high-risk human papillomavirus (hrHPV), HPV genotypes 16, 18, 31, 33, 35, 39,
87 45, 51, 52, 56, 58, 59, 66, 68, and 73, has become the leading etiologic factor of OPSCC [2, 20-
88 28].

89 Since the World Health Organization recognized the causative link between 15 hrHPV
90 genotypes and the occurrence of OPSCC in 2007 [29], hrHPV has been accepted as a principal
91 etiological cause of this cancer [2, 20, 22, 24, 30-34]. HPV-driven OPSCC is markedly on the
92 rise [2, 4, 10, 22-24, 35-37]. In the United States, the estimated proportion of positive cases has

93 increased from 20% in 1990 to >70%, where hrHPV now represents the most common cause of
94 OPSCC [2, 7, 27, 36, 38]. Countries in Western Europe have observed similar trends [7, 13, 36,
95 37, 39-41]. Interestingly, these changes have been accompanied by an increment in the survival
96 rates for OPSCC [36, 42, 43]. HPV-positive patients have a significantly better response to
97 treatment (radiation therapy and chemotherapy as well as surgery) and a more favorable
98 prognosis than those diagnosed with HPV-negative OPSCC [23, 25, 27, 28, 35, 42, 44-50].

99 Despite these observations, recent studies from Taiwan suggest that its high OPSCC rates
100 continue to increase predominantly due to heavy alcohol drinking, cigarette smoking, and betel
101 quid chewing as etiologic factors [9, 51-54]. The strong influence of these risk habits has limited
102 the search for a viral etiology in this population. There have been a few studies indicating that
103 hrHPV is an emerging risk for head and neck cancer in South-East Asia, with a prevalence of
104 HPV-positive OPSCC reported to be absent or present in 12.6% [55-57] to 34% [57-62] of
105 OPSCCs. In this study, we conducted a retrospective cohort analysis to interrogate the
106 prevalence and significance of HPV-driven OPSCC in tissue samples collected from a single
107 major referral site in Taiwan over a period of 18 years. We evaluated the association between
108 clinical characteristics and traditional risk factors (alcohol, smoking, and betel quid) with HPV-
109 associated OPSCC in Taiwan. HPV results were correlated with risk factor exposure for
110 outcomes and survival analysis.

111

112 **Methods**

113 **Case identification and study design**

114 This study was performed on a retrospective cohort of OPSCC cases diagnosed from
115 March 1998 to February 2016 at the Chang Gung Memorial Hospital (CGMH)-Linkou in

116 Taoyuan, Taiwan (Taiwan cohort), as described in Figure 1. CGMH is the largest cancer center
117 and a major referral center in Taiwan. Case selection was not a source of bias as we identified
118 OPSCC tumors with a confirmed primary site in the oropharynx using hospital electronic and
119 pathology records from all patients that underwent curative-intent therapy at this tertiary
120 healthcare center. Patients with unknown primary site (T0 or Tx) were excluded. Primary tumors
121 were biopsied only or resected by surgery and collected for histopathological diagnosis. All
122 patients with available pathology-archived tissue and known clinical records were included in
123 this cohort (Fig 1). In total, 541 OPSCC tumors were retrieved, sectioned, anonymized, and
124 shipped to the University of Michigan for HPV and p16 testing. Five non-squamous cell
125 carcinoma cases were excluded from the study based on their pathological classification and
126 histopathological re-assessment of the submitted sections.

127

128 **Fig 1. Flow diagram of cases included in the Taiwan retrospective cohort and study design.**

129 ¹Results missing due to absent slide or tissue core, or major artifacts that prevented evaluation.

130 ²Results missing due to absent DNA or invalid test. OPSCC, oropharyngeal squamous cell
131 carcinoma; HPV, human papillomavirus; FFPE, formalin-fixed, paraffin-embedded; IHC,
132 immunohistochemical staining; PCR-MA, multiplex PCR-MassArray.

133

134 To analyze the contribution of hrHPV on these OPSCC cases, qualitative data on the
135 common risk factors, alcohol consumption, smoking, and betel quid chewing habits were
136 collected. However, because of the retrospective nature of the study, and a change to an
137 electronic record system, data on the quantity of alcohol, smoking, betel quid consumption, or
138 comorbidities could not be retrieved for a large proportion of the patients. Smoking is the only

139 use of tobacco in Taiwan because betel quid preparations do not contain tobacco and tobacco
140 chewing is an extremely uncommon behavior [9, 63]. Demographic information, including
141 patient characteristics (age at diagnosis, and gender), as well as clinical information (stage, tumor
142 site, initial treatment, and outcomes for recurrence, metastasis, and death), were compiled from
143 patient records. Cases were staged at diagnosis according to the seventh edition of the American
144 Joint Cancer Committee (AJCC) [64].

145

146 **HPV interrogation**

147 All OPSCC tumors were evaluated for the presence of HPV by two complementary
148 methods: p16 testing and detection of HPV DNA types [65-67] (Fig 1). Results from each
149 determination were blinded to the investigators to avoid bias. Tumors with either p16 and/or
150 HPV DNA positivity were defined as HPV-positive.

151 **Detection and genotyping of HPV DNA by Multiplex PCR-MassArray (PCR- 152 MA)**

153 DNA was isolated from tissue curls of formalin-fixed, paraffin-embedded (FFPE) tumor
154 specimens. Two to seven 10- μ m FFPE sections were combined in each extraction with AllPrep
155 DNA/RNA FFPE Kit (Catalog No. 80234, QIAGEN, Germantown, MD, US), according to the
156 manufacturer's recommendations. DNA was eluted in DNase-free water and stored at -20 °C
157 until testing. DNA concentration was measured by a Qubit 2.0 Fluorometer (Catalog No.
158 Q32866, Invitrogen-Thermo Fisher Scientific Inc., Waltham, MA, US) and the Qubit dsDNA HS
159 Assay Kit (Catalog No. Q32851, Invitrogen-Thermo Fisher Scientific Inc., US).

160 Samples were examined for the presence of HPV DNA and genotyped by PCR-MA
161 analysis, a very sensitive, high-throughput method based on competitive PCR and probe-specific

162 single-base extension coupled with MALDI-TOF mass spectrometry [65-67]. The PCR-MA
163 assay is designed to detect 15 high-risk (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,
164 68, and 73), and 2 low-risk (HPV 6 and 11) HPV types, and a possible high-risk subtype
165 (HPV90), as previously described by our laboratory [65-67]. Reactions were prepared with 20 ng
166 of DNA and carried out in quadruplicates in an area physically separated from DNA isolation.
167 Tests were run using a Mass Array 384-format System (Agena Bioscience Inc., San Diego, CA,
168 US). Specimen acceptability was determined using human glyceraldehyde-3-phosphate
169 dehydrogenase (GAPDH) DNA control.

170 **p16 testing by immunohistological analysis**

171 FFPE tissue sections (4- μ m) were used for p16 immunostaining with a specific antibody
172 against Protein Cyclin-dependent kinase inhibitor 2A (CDKN2A), also known as p16INK4a, as a
173 surrogate for transcriptionally and translationally active HPV [68]. The immunohistochemical
174 (IHC) staining was carried out manually using the clinically validated CINtec-p16 (E6H4)
175 antibody (pre-diluted, Ref. No. 725-4713, Ventana Medical Systems Inc., Tucson, AZ, USA) as
176 stated by the supplier's protocol. The CINtec-p16 primary antibody was incubated for 1 hour at
177 room temperature followed by washing and appropriate horseradish peroxidase-labeled
178 secondary antibody for 30 minutes at room temperature. All slides were stained with 3,3'-
179 diaminobenzidine for 1-5 minutes, followed by hematoxylin counterstain.

180 p16 IHC was examined for each slide at 200x and 400x magnification according to the
181 2018 recommendations of the College of American Pathologists [68]. p16 expression was scored
182 as positive if $\geq 70\%$ of the tumor cells exhibited strong and diffuse nuclear and cytoplasmic p16
183 immunoreactivity (S1 Fig).

184

185 **Statistical analysis**

186 Two-sided Fisher's exact test (F) was used to analyze the relationship between p16 and
187 HPV DNA results. The association between HPV prevalence and study year was evaluated by
188 two-sided simple linear regression and Spearman rank correlation (ρ). Data for HPV status,
189 alcohol consumption, cigarette smoking, betel quid chewing, age, gender, T-stage, N-stage,
190 disease site, initial treatment, and clinical outcomes were collected as covariates. Standard
191 descriptive statistics were performed for each covariate collected. Differences in the distribution
192 of covariates by HPV status were tested by two-sided t-test (continuous measures) or Pearson's
193 chi-squared test (χ^2) (categorical/binary). Time-to-event outcomes were defined beginning from
194 date of pathology diagnosis to death from any cause (Overall Survival), or from date of
195 pathology diagnosis to date of first recurrence or death (Disease-Free Survival); subjects alive
196 with no event were censored at date of last follow-up. The Kaplan-Meier method and log-rank
197 tests were used to estimate survival probabilities and plot survival distributions. Cox proportional
198 hazard models and hazard ratio (HR) estimations for time up to 5 years post-diagnosis were
199 performed to test relative hazards between groups in the whole cohort and in subsets stratified by
200 HPV status or other risk factors (alcohol consumption, cigarette smoking, and/or betel quid
201 chewing), adjusting for age, T- and N-stage. Cases with no HPV status data (p16 or HPV DNA),
202 $N = 13$, were excluded, leaving 528 cases eligible for Chi-squared and survival calculations.
203 Tests were also performed to examine the variates and survival distributions by gender.
204 Statistical analyses were conducted in SAS v9.4 (SAS Institute Inc., Cary, NC, US) using R
205 v3.6.1 (RStudio, Boston, MA, US) for graph generation, or GraphPad Prism v8.3.0 (GraphPad
206 Software, San Diego, CA, US). Statistical tests were performed using 95% confidence intervals
207 and a 5% significance level.

208

209 **Ethics statement**

210 This retrospective study was approved by the Institutional Review Boards of the
211 University of Michigan Medical School and the Chang Gung Memorial Hospital and conducted
212 in compliance with the ethical guidelines of the World Medical Association's Declaration of
213 Helsinki (1964, amended in 2013) and local regulations. Additional patient consent was not
214 required by the institutional review boards as this OPSCC cohort comprised secondary use of
215 tissue specimens with unidentified chart data. All information stripped of personal identifiers to
216 ensure that the data cannot be linked to individual cases in this cohort, are available in the
217 supplementary S1 Table. The procedures described in this manuscript followed the reporting
218 standards for human subject research of the EQUATOR Network, which are detailed in the
219 STROBE report for this study (S1 Checklist).

220

221 **Results**

222 **HPV status and clinical characteristics**

223 A total of 546 OPSCC cases were obtained from an unbiased retrospective chart review
224 of individuals treated with standard of care therapy from March 1998 to February 2016 at the
225 CGMH in Taiwan (Taiwan cohort). Among these cases, five were not OPSCC according to the
226 pathology records and slide review; these were excluded as they did not fulfill our inclusion
227 criteria. Therefore, the final study cohort included 541 OPSCC cases (Fig 1, S1 Table).

228 The presence of HPV in FFPE tumor sections of oropharyngeal cancer was assessed by
229 IHC staining for p16, a surrogate marker for HPV [68] (Fig 1, S1 Fig, S1 Table). HPV genotypes

230 were identified by PCR-MA [65-67] using tumor genomic DNA (Fig 1, S1 Table). Of the 541
 231 OPSCC tumors tested, p16 was positive in 115 (21.3%), negative in 355 (65.6%), and 71
 232 (13.1%) could not be scored. HPV detection and genotyping showed that 134 (24.8%) tumors
 233 were HPV-positive, 379 (68.4%) HPV-negative, and 37 (6.8%) had insufficient DNA (failed to
 234 amplify the GAPDH control) (Fig 1, S1 and S2 Tables). Of the 134 positives, HPV16 was found
 235 alone in 103 (76.9%) and HPV58 was the second most frequently found in 10 (7.5%) tumors.
 236 HPV66, HPV59, HPV45, HPV39, HPV34, HPV31, HPV18, and HPV6 were also found in 13
 237 (9.7%) individual tumors. HPV16 was also present together with other HPV genotypes (HPV6,
 238 HPV18, HPV35, HPV58, or HPV59) in 8 (6.0%) tumors (Table 1, S1 Table). These results
 239 indicate, that aside from low-risk HPV6, there are diverse oncogenic HPV genotypes in Taiwan
 240 OPSCCs.

Table 1. HPV genotypes frequency.

HPV Genotype	Frequency	Percent	Cumulative Frequency	Cumulative Percent
HPV16	103	76.87	103	76.87
HPV58	10	7.46	113	84.33
HPV35	3	2.24	116	86.57
HPV18	2	1.49	118	88.06
HPV31	2	1.49	120	89.55
HPV45	2	1.49	122	91.04
HPV59	2	1.49	124	92.53
HPV66	1	0.75	125	93.28
HPV6	1	0.75	126	94.03
HPV16 HPV58	2	1.49	128	95.52
HPV16 HPV18	2	1.49	130	97.01
HPV16 HPV6	2	1.49	132	98.50
HPV16 HPV35	1	0.75	133	99.25
HPV16 HPV59	1	0.75	134	100

241 Altogether, p16 overexpression was strongly correlated with HPV status in OPSCC, as
 242 the concordance between p16 and HPV DNA testing was 94.9% (423 out of 446, $F < 0.0001$, S2

243 Table). Therefore, for this study, we defined HPV positivity as either positive by p16 or HPV
244 DNA test. Thus, we had 528 OPSCC tumors with HPV status (positive or negative) called. HPV
245 status (p16 and HPV DNA) data were not obtained for thirteen cases and were not included in
246 the analysis (Fig 1, S1 and S2 Tables). The prevalence of HPV-positive OPSCC in the whole
247 cohort was 28.4% (150 out of 528) (Fig 1). Interestingly, when we examined the yearly
248 occurrence of HPV-positive OPSCC, we found that there was a trend for an increase over the 18
249 years of study, but it failed to reach statistical significance (Fig 2, S3 Table). However, the same
250 trend is significant when we examined the yearly occurrence of p16 alone (Fig. 2, S3 Table).
251 Nonetheless, this result should be carefully interpreted as 71 cases are missing data for p16 (S1-
252 S3 Tables). We also observed a clear increment in the number of HPV-negative cases that drive
253 the growing incidence of OPSCC rates in Taiwan, thereby obscuring the gradual rise of HPV-
254 positive OPSCCs. Nevertheless, our results demonstrate an increasing role of oncogenic HPV
255 and its causal role as an etiologic factor of OPSCC in this population.

256

257 **Fig. 2. Yearly HPV occurrence among OPSCC cases by HPV DNA and/or p16 (A) or p16**
258 **alone (B).** The graphs show the correlation between the total frequency of HPV-positive (HPV+)
259 and HPV-negative (HPV-) OPSCC cases, and the study years (see S3 Table). HPV status was
260 assessed by (A) HPV DNA and p16 testing (N = 528) or (B) p16 scoring (N = 458). The
261 association was evaluated in the Taiwan cohort from March 1998 to February 2016 by
262 Spearman's coefficient (ρ) and linear regression (R^2). (A) HPV-: $\rho = 0.6953$, $p = 0.0014$; $R^2 =$
263 0.5201 , $p = 0.0007$. HPV+ $\rho = 0.4093$, $p = 0.0917$; $R^2 = 0.1952$, $p = 0.0664$. (B) p16-: $\rho =$
264 0.6991 , $p = 0.0012$; $R^2 = 0.5555$, $p = 0.0004$. p16+ $\rho = 0.4741$, $p = 0.0469$; $R^2 = 0.2455$, $p =$
265 0.0365 .

266

267 Next, we assessed the demographic and clinical features of the whole cohort, as listed in
268 Table 2. In our study, males represented 94% (507 out of 541) of all cases, and the average age at
269 tumor diagnosis was 53.5 years old, with 66% of the tumors, diagnosed in individuals of 41-60
270 years of age (358 out of 541). Over half of the tumors, 58% (315 out of 541), were biopsied or
271 resected from the tonsils, followed by 24% (132 out of 541) from the soft palate, 17% (90 out of
272 541) from the base of the tongue, and 1% (4 out of 541) from other non-specified locations in the
273 oropharynx. Unknown primary tumors diagnosed by neck node pathology were not included in
274 the tumor retrieval, which may account for the relatively low incidence of base of tongue tumors
275 in this cohort. The large majority of the cohort had a history of previous exposure to known risk
276 factors: 51% (278 out of 541) drank alcohol, 83% (448 out of 541) smoked, and 65% (349 out of
277 541) chewed betel quid (Table 2, S4 Table). Most prominently, 87% (468 out of 541) of these
278 individuals used more than one of alcohol, and/or tobacco, and/or betel quid concomitantly.
279 Never-smokers, never-drinkers, and never-betel quid chewers accounted for a small 13% (73 out
280 541) of the cases (S4 Table). Because of the high density of risk factors, and their combined
281 exposure, we were unable to separate their individual effects. Therefore, only 1% (7 out of 541)
282 of the Taiwan cohort was exposed to alcohol without smoking or betel quid chewing, 11% (60
283 out of 541) solely smoked, and 1% (5 out of 541) only consumed betel quid (S4 Table).

Table 2. Demographic and clinical characteristics.

		Whole cohort N = 541	Stratified by HPV N = 528		
Variable		N (%)	HPV- N = 378 N (%)	HPV+ N = 150 N (%)	p-Value
Age [Mean (std)]	Years	53.5 (10.4)	52.7 (10.1)	55.5 (10.6)	0.004
Age	21-40	42 (8%)	32 (8%)	9 (6%)	0.18
	41-60	358 (66%)	255 (67%)	94 (63%)	
	61 to 86	141 (26%)	91 (24%)	47 (31%)	
Stage	1	29 (5%)	22 (6%)	7 (5%)	0.40
	2	68 (13%)	47 (12%)	20 (13%)	
	3	84 (16%)	61 (16%)	16 (11%)	
	4	359 (66%)	248 (66%)	106 (71%)	
T-stage	1	64 (12%)	47 (12%)	15 (10%)	0.008
	2	187 (35%)	117 (31%)	69 (46%)	
	3	108 (20%)	75 (20%)	27 (18%)	
	4	181 (34%)	139 (37%)	38 (26%)	
N-stage	0	169 (31%)	122 (32%)	41 (28%)	0.22
	1	77 (14%)	59 (16%)	16 (11%)	
	2	246 (46%)	165 (44%)	77 (52%)	
	3	48 (9%)	32 (8%)	15 (10%)	
Disease Site	Soft Palate	132 (24%)	111 (29%)	19 (13%)	<0.0001
	Tongue Base	90 (17%)	67 (18%)	22 (15%)	
	Tonsil	315 (58%)	196 (52%)	109 (73%)	
	Oropharynx	4 (1%)			
	other		4 (1%)	0 (0%)	
Initial Treatment	Chemoradiation	403 (75%)	279 (75%)	114 (77%)	0.29
	Radiation	89 (17%)	59 (16%)	27 (18%)	
	Surgery	43 (8%)	35 (9%)	8 (5%)	
Risk Factors					
Alcohol	Yes	278 (51%)	213 (56%)	56 (37%)	<0.0001
Smoke	Yes	448 (83%)	339 (90%)	97 (65%)	<0.0001
Betel Quid	Yes	349 (65%)	285 (75%)	53 (35%)	<0.0001
Alcohol and/or Smoke and/or Betel Quid	Yes	468 (87%)			
			351 (93%)	105 (70%)	<0.0001

<i>Outcomes</i>		
Death	310	237 65
recurrence	99	82 12
neck recurrence	82	67 13
Metastasis	55	39 13

HPV positivity is defined as HPV DNA-positive and/or p16-positive. *p*-values derived from t-test (continuous measures) or Chi-square test (categorical) by HPV status, missing values were excluded. TNM classification, according to the 7th AJCC staging edition: "T" (T classification), "N" (N classification), and "Stage" (overall stage). Because all cases were presented with no metastasis (M0), there is no heading for M. The individual variables "Alcohol", "Smoke, and "Betel Quid" were not adjusted for exposure to the other two risk factors.

284

285 We then examined the clinical determinants of HPV status (Table 2). When compared to
 286 HPV-negative cases, HPV-positive tumors (HPV DNA-positive and/or p16-positive) had a
 287 slightly higher average age at diagnosis (55.5 vs. 52.7 years, *p* = 0.004), with most individuals
 288 presenting between 41-60 years old in both groups (67% vs. 63%, *p* = 0.18), and slightly lower
 289 T-stage (majority of T2 cases vs. T4, *p* = 0.008). The HPV-positive tumors were also most
 290 frequently located in the tonsils (73% vs. 52%, *p* < 0.0001); and presented with lower exposure
 291 to all the risk factors including alcohol (37% vs. 56%, *p* < 0.0001), smoking (65% vs. 90%, *p* <
 292 0.0001), and betel quid (35% vs. 75%, *p* < 0.0001) (Table 2, S4 Table). Although the number of
 293 females was far lower, representing only 6% (34 out of 541) of the cases (Table 2), they showed
 294 pronounced differences with males (S5 Table). The majority, 62% (21 out of 34) of tumors from
 295 females, but a minority, 25% (129 out of 507) of tumors from males, were HPV-positive (*p* <
 296 0.0001). The proportion of tonsil tumors was also higher in females than in males (85% vs. 56%,
 297 *p* = 0.01), and were more likely to be N3 (*p* = 0.03) (AJCC 7th edition). The females had lower
 298 exposure to alcohol (18% vs. 54%, *p* < 0.0001), smoking (21% vs. 87%, *p* < 0.0001), and betel
 299 quid (12% vs. 68%, *p* < 0.0001); and were more likely to be never users of these high risk
 300 carcinogens. Females also tended to be older at diagnosis (mean: 58.7 years vs. 53.1 years, *p* =

301 0.002). Among both males and females the majority of cases were of 41-60 years of age (64% v.
302 66%, $p = 0.13$) (S5 Table). There was also a slightly better prognosis for the female group (OS:
303 log-rank $p = 0.05$; DFS: log-rank $p = 0.07$) (S2 Fig), but given the small group size ($N = 34$), this
304 observation should be carefully interpreted.

305

306 **The role of HPV status and associated risk factors on OPSCC**

307 **outcome**

308 First, we determined if HPV status had survival benefits on OPSCC by multivariable and
309 Kaplan-Meier analysis (Fig 3, S6 Table). Compared to HPV-negative cases, patients with HPV-
310 positive OPSCC had significantly higher overall survival (HR 0.58, 95% CI 0.42 to 0.81, $p =$
311 0.001; log-rank $p < 0.0001$) and disease-free survival (HR 0.54, 95% CI 0.40 to 0.73, $p < 0.0001$;
312 log-rank $p < 0.0001$) for up to 5-year post-diagnosis, suggesting that HPV-positivity was an
313 independent predictor for better prognosis.

314

315 **Fig 3. HPV-positive OPSCC is associated with increased survival time.** (A-B) Up to 5-year
316 overall survival (OS) and disease-free survival (DFS) prognostic outcomes of the HPV variable
317 in the whole OPSCC Taiwan cohort. HPV positivity is defined as HPV DNA-positive and/or
318 p16-positive. (A) Table includes the multivariable hazard probabilities analyzed using Cox
319 survival models and hazard ratio (HR) estimations, visualized by forest plots. The complete
320 analysis is found in S6 Table, where estimates were reported for full model with all covariates
321 (HPV status, alcohol, smoking, betel quid, age, N- and T-stage) included as fixed effects. (B)
322 Kaplan-Meier survival analysis. Plots represent the results for up to 5-year OS (left) and DFS
323 (right) comparison between HPV-negative (HPV-) and HPV-positive (HPV+) groups. Log-rank

324 analysis was used to compare the survival distributions (log-rank p -values are in the plots). HPV-
325 , HPV-negative; HPV+, HPV-positive.

326 Similar analyses also revealed that consumption of alcohol was a strong negative
327 prognostic factor for both up to 5-year overall survival (OS) (HR 2.06, 95% CI 1.54 to 2.74, $p <$
328 0.0001; log-rank $p < 0.0001$) and disease-free survival (DFS) (HR 1.72, 95% CI 1.33 to 2.24, $p <$
329 0.0001; log-rank $p < 0.0001$) (Fig 4, S6 Table). Surprisingly, smoking, and betel quid chewing
330 had no predictive effects (Fig 4, S6 Table). Smoking did not have statistical significance for
331 worse overall survival (HR 0.76, 95% CI 0.50 to 1.14, $p = 0.18$; log-rank $p = 0.24$) and disease-
332 free survival (HR 0.81, 95% CI 0.56 to 1.17, $p = 0.26$; log-rank $p = 0.40$). Betel quid exposure
333 showed no effect on survival by multivariable analysis (OS: HR 0.92, 95% CI 0.67 to 1.27, $p =$
334 0.60; log-rank $p < 0.05$ – DFS: HR 0.90, 95% CI 0.66 to 1.21, $p = 0.46$; but by Kaplan-Meier
335 analysis betel quid use, just reached significance log-rank $p < 0.05$).

336

337 **Fig 4. Alcohol is associated with reduced OPSCC survival time.** (A-D) Prognostic outcomes
338 of the alcohol, smoking, and betel quid variables within the whole cohort. We analyzed up to 5-
339 year overall survival (OS) and disease-free survival (DFS) outcomes for high-risk habits. (A)
340 Table includes the multivariable hazard probabilities analyzed using Cox survival models and
341 hazard ratio (HR) estimations, visualized by forest plots, where estimates were reported for full
342 model with all covariates (HPV status, alcohol, smoking, betel quid, age, N- and T-stage)
343 included as fixed effects. The complete analysis is found in S6 Table. (B-D) Kaplan-Meier
344 survival analysis. Plots represent the results for up to 5-year OS (left) and DFS (right)
345 comparison between alcohol (B), smoke (C), and betel quid (D) groups. Log-rank analysis was
346 used to compare the survival distributions (log-rank p -values are in the plots).

347

348 Additional multivariable survival analysis and Kaplan-Meier estimations for alcohol,
349 smoking, and betel quid groups, controlled for HPV status, were also performed (Fig 5, S3 Fig,
350 S7 Table). Alcohol use had an adverse effect on outcome in both HPV-positive and HPV-
351 negative groups, but HPV was associated with longer OPSCC survival time (survival by alcohol
352 within HPV groups, OS: HPV-positive log-rank $p = 0.0007$, HPV-negative long rank $p < 0.0001$
353 – DFS: HPV-positive log-rank $p = 0.02$, HPV-negative long-rank $p = 0.0005$). No predictive
354 associations were found for tobacco (survival by smoking within HPV groups, OS: HPV-positive
355 log-rank $p = 0.44$, HPV-negative long rank $p < 0.28$ – DFS: HPV-positive log-rank $p = 0.49$,
356 HPV-negative long-rank $p = 0.18$) or betel quid chewing (survival by betel quid within HPV
357 groups, OS: HPV-positive log-rank $p = 0.41$, HPV-negative log rank $p < 0.68$ – DFS: HPV-
358 positive log-rank $p = 0.21$, HPV-negative long-rank $p = 0.46$) based on HPV status. Most
359 importantly, our data demonstrate that the prognostic benefit of HPV positivity persists in the
360 presence of risk factors, alcohol, and tobacco, and betel quid (DFS by HPV within risk groups:
361 alcohol yes log-rank $p = 0.008$, alcohol no log-rank $p = 0.007$; smoking and/or betel quid yes
362 log-rank $p = 0.0006$, smoking and/or betel quid no log rank $p = 0.01$) (S4 Fig, S8 Table).
363 Furthermore, among non-drinkers, non-smokers, and non-betel quid chewers, HPV-positive
364 OPSCC had the best outcomes. In sum, our study shows that hrHPV has a causal role but also
365 carries a significant prognostic benefit for OPSCC in this Taiwan cohort.

366

367 **Fig 5. In alcohol users, HPV is associated with improved OPSCC survival time. (A-C)**

368 Prognostic outcomes of the alcohol, smoking, and betel quid variables within HPV risk groups.

369 HPV positivity is defined as HPV DNA-positive and/or p16-positive. We analyzed up to 5-year

370 overall survival (OS) and disease-free survival (DFS) outcomes. (A) Table includes the
371 multivariable hazard probabilities analyzed using Cox survival models and hazard ratio (HR)
372 estimations, adjusted for age, T- and N-stage, and visualized by forest plots. (B-C) Kaplan-Meier
373 survival analysis. Plots represent the results for up to 5-year OS (B) and DFS (C) comparison
374 between HPV groups stratified by alcohol groups. Log-rank analysis was used to compare the
375 survival distributions (log-rank p-values are in the plots). The complete analysis is found in S7
376 Table and S3 Fig. HPV-, HPV-negative; HPV+, HPV-positive.

377

378 **Discussion**

379 In Western countries, the prevalence of HPV-driven OPSCC has been rising drastically in
380 the last 4 decades to become one of most common head and neck cancers [2, 4, 10, 22-24, 35-
381 37]. Those affected by OPSCC suffer great losses due to aggressive treatment, morbidity, and
382 death [20, 28, 35, 36, 42, 43, 45, 47-50, 69, 70]. Still, the extent of this disease and its public
383 health impact are not well understood outside North America and Western Europe. In this
384 retrospective cohort study, we performed a comprehensive investigation of the impact of HPV-
385 driven OPSCC in a cohort from the largest cancer treatment center in Taiwan from 1998 to 2016.
386 We found that HPV was present in 28.4% of the tumors, with a trend for incremental occurrence
387 over time. HPV16 was the most prevalent genotype (82.8%), followed by HPV58 (7.5%), and
388 other diverse genotypes. HPV-positive OPSCCs occurred in higher proportion in females and
389 presented with different clinical features than their HPV-negative counterparts, including
390 reduced engagement in risk behaviors such as alcohol drinking, cigarette smoking, and betel quid
391 chewing. Additional outcome analysis of the entire cohort showed that HPV-positivity was
392 associated with a notably higher survival rate. Surprisingly, only alcohol, but not smoking or

393 betel quid, were strongly associated with a worse prognosis. The strong prognostic benefit of
394 HPV remained present but reduced in the presence of the associated risk factors alcohol,
395 smoking, and betel quid.

396 Many studies have demonstrated an increment of HPV-driven OPSCC in numerous
397 countries, showing considerable geographical variability in the proportion of cases over time [36,
398 71, 72]. Recent estimates calculate the worldwide prevalence of HPV-positive OPSCC between
399 18% and 35.6% [24, 73]. Reports from the United States, demonstrate a marked incremental
400 variability over the years, from 20% by 1990 to over 70% of OPSCCs being currently caused by
401 hrHPV [2, 7, 27, 36, 38]. Studies at the University of Michigan alone have shown a prevalence
402 of 82.3% [27]. Reports from other developed countries and Western Europe, such as the United
403 Kingdom and Finland, have observed a similar increment in prevalence of HPV-positive OPSCC
404 during the last decades [7, 13, 36, 37, 39-41, 72]. Differently, in South-East Asia, recent studies
405 have shown a slower trend for these increments, with the proportion of HPV-positive OPSCC
406 varying from 0% to 34% in various populations [9, 20, 57-62]. In neighboring Hong Kong,
407 hrHPV has been found in 20.8% of tumors [59]. Likewise, a limited number of studies from
408 Taiwan, suggested that hrHPV is a rising etiological factor in head and neck cancer, including
409 OPSCC [55-57]. Particularly, Chien et al. demonstrated that in the early 2000s, 12.6% of the
410 squamous cell tonsillar carcinomas were positive for hrHPV in Taiwan [57]. Here, our study
411 indicates that the proportion of HPV-positive OPSCCs in the cosmopolitan Taiwanese
412 population presented an incremental trend from 1998 to 2016. With an overall prevalence of
413 28.4%, our results suggest similar proportions in Taiwan to those observed in 1990 in the US
414 [38]. Given this global historical data, we anticipate that Taiwan will also have a significant
415 marked increment going forward in the rates of HPV-related OPSCC. Although the observed

416 prevalence is three-fold lower in our Taiwan cohort compared with Western countries, this is
417 higher than that reported for the US Asian population (12.8%) [46]. Our results also showed high
418 concordance between HPV-DNA and p16 surrogate marker positivity (94.9%, 423 out of 446, F
419 < 0.0001 , S2 Table). p16 IHC is a robust surrogate marker and predictor for HPV-caused
420 OPSCC, with very low percentage of false negatives (4%) [68]. These findings indicate that
421 HPV was present in the tested specimens and a likely etiological driver of oropharyngeal
422 carcinogenesis, suggesting that HPV is not likely a passenger virus in most of these tumors. Still,
423 several cases had discordant results: 2.2% (12 out of 541) tumors tested p16 negative but had
424 HPV DNA positive results, while 2.0% (11 out of 541) tumors were p16 positive but had HPV
425 DNA negative results (S2 Table). There are potential explanations for to account for the
426 discordant cases. The p16-negative/HPV DNA positive cases may represent tumors where HPV
427 is an incidental inactive passenger and not a causal driver of disease, or tumors for which p16 has
428 been inactivated by another mechanism. Possible explanations for the p16-positive/HPV DNA
429 negative cases could be that HPV DNA is in fact present in the tumor, but is mutated in the
430 region where amplification/detection occurs for the test, or that p16 is upregulated by a different
431 pathway or mechanism (something other than HPV).

432 Of important note, our study sheds light on the causal association between HPV
433 genotypes and OPSCC in Taiwan. It is well-recognized that certain high-risk viral genotypes are
434 carcinogenic and highly associated with the development of OPSCC [2, 36], especially HPV16
435 [3, 11, 29, 42, 73, 74]. In line with the predominant worldwide prevalence of HPV16 in OPSCC,
436 this has also been identified in the majority of cases from Southern China [59], and previous
437 reports in tonsillar squamous cell carcinomas in Taiwan [57]. Coincidentally, in our current
438 study, HPV16 accounted for the vast majority (82.8%) of HPV-positive OPSCCs, followed by

439 HPV58 in 7.5% of cases. Apart from HPV16 and HPV58, other oncogenic hrHPV genotypes
440 were infrequent, and HPV18, which often causes cancer in the Western world, was only present
441 in a very small proportion of the specimens (1.5% alone and 1.5% in combination with HPV16).
442 Interestingly, our previous work has shown similar low proportion of HPV18-positive OPSCCs
443 in the United States [65]. In addition, it has been reported that oral HPV infections in smokers
444 and betel nut chewers, are mainly caused by HPV16. Still, HPV58 has been found at a low
445 percentage in Northern Taiwan, especially in patients with the highest exposure to traditional
446 habits that increase cancer risk [56]. Likewise, a literature search for the genotype prevalence of
447 other HPV-related cancers within East Asia and Taiwan, showed that in Northern China HPV16
448 is dominant in cervical carcinomas [75, 76]. This prevalence decreases in the Southern regions of
449 the country [20, 77], to become similar to the observed occurrence of other important genotypes
450 in Taiwan, HPV52 and HPV58 [78]. Although HPV16 has been found in over 80% of cervical
451 cancers in Asia, it has been reported in only 50% of the cervical cancers in Taiwan [79]. In this
452 population, HPV58 is the second or the third most common genotype found in cervical
453 malignancies (~20%, together with HPV18) and cervical HPV infections, but it is rare in other
454 parts of the world [80-83]. HPV52, usually found in cervical cancers in East Asia [59, 84, 85]
455 was included in the test panel, but was not detected in our Taiwanese cohort. This particular
456 distribution of HPV genotypes suggests tissue or geographic specificity for HPV16 and HPV58
457 in Taiwan, where HPV is becoming an increasingly important etiologic factor of OPSCC.

458 As part of our study, we also analyzed the clinical determinants of HPV positivity in
459 OPSCC. This malignancy is considered one of the emerging causes of cancer death in Asian and
460 Taiwan males [9, 55]. Curiously, even when most of the cases in our cohort were males (94%),
461 females had most commonly HPV-positive tumors and presented reduced alcohol, smoking, or

462 betel quid habits. There was also a trend for slightly better prognosis within the female group (S2
463 Fig). While the better prognosis in women may be related to better health utilization of women
464 over men, our results indicate that OPSCC is a disease that also affects Taiwanese women, and
465 more research is necessary to address their specific clinical management. Moreover, HPV-
466 positive tumors were associated with a slightly higher age at diagnosis (mean = 55.5 years) than
467 HPV-negative tumors. This represents another particularity since hrHPV has been historically
468 associated with the onset of OPSCCs in younger, middle-aged individuals [23, 35, 39, 44, 59,
469 86], even in Taiwan, where the average age at diagnosis has been reported between 40 and 50
470 years of age [55]. Despite this belief, new studies from Western countries have contradicted
471 these trends by demonstrating that the highest HPV prevalence occurs in patients above 55 and
472 even 70 years of age [19, 87, 88]. This suggests a similar changing epidemiology in Taiwan, with
473 a possible shift of sexual onset at a later age, reduced number of sexual partners in life, or
474 reinfection later in life. Even when our data diverge from previous reports, these agree with
475 studies from Southern China and Western countries indicating a significant correlation between
476 HPV status and earlier primary tumor stage (T-stage) [3, 59]. However, our results demonstrate a
477 higher T-stage within the entire cohort (T3-4 instead of T1-2), although the most common T
478 class among HPV-positive tumors was T2 (46%) but among HPV-negative tumors the most
479 common T-class was T4 (37%). N-stage did not present a significant association with HPV
480 status. These HPV-positive tumors were associated with the tonsils as their primary location,
481 denoting site-specificity, as also indicated in previous observations from Taiwan [55]. Thus, our
482 results indicate that HPV-driven OPSCC is a clinically unique disease with distinctive features to
483 this cohort of Taiwanese patients.

484 Furthermore, the carcinogenic effect of the risk factors alcohol, smoking, and betel quid
485 has been very well characterized. These are considered the main etiological agents of HPV-
486 negative OPSCC [6-13, 15-17]. It has been proposed that the observed increasing rates of
487 OPSCC in East Asia and Taiwan are related to the excessive and extensive use of alcohol,
488 smoking, and betel quid (which does not contain tobacco) [9, 51-54, 63]. Previous studies in
489 Taiwan report that exposure to these agents represents a high risk for developing primarily
490 intraoral cancer [9, 57]. For this reason, it was not surprising to observe that above two thirds of
491 the OPSCC cases in our study tested negative for HPV and had a prominent smoking (83%),
492 betel quid chewing (65%), or alcohol drinking (51%) history (Table 2, S4 Table). Earlier
493 findings also showed a similar proportion of alcohol drinkers within the Taiwanese male
494 population [9]. Interestingly, in our cohort, 87% of the individuals with OPSCC used these
495 chemical carcinogens in combination. Only 1% of the cohort consumed alcohol or betel quid
496 alone, and 11% only smoked (S4 Table). Although these historically causative risk factors are
497 still very prominent in Taiwan, we observed that only alcohol consumption is a significant
498 determinant of worse prognosis. This was surprising, as tobacco smoking has been found to be
499 the most important predictor of unfavorable outcome and risk factor in OPSCC, as patients with
500 mutant p53 have a reduced capacity to repair DNA [3, 25, 27, 44, 89]. The reasons for the
501 dwarfed effect of smoking and betel quid as negative drivers remain elusive, but they may reside
502 in the high proportion of smokers in the cohort (83%) or individuals with a complex combination
503 of risk factors, as shown in S4 Table. This makes it impossible to separate the individual effects
504 of the carcinogens, alcohol, tobacco, and betel quid, which could have additive effects on DNA
505 damage and potentiate the negative impact of alcohol. Alternatively, alcohol could also represent
506 a surrogate for lack of social support or socioeconomic disadvantage. Additionally, our findings

507 reveal that HPV-positive tumors were less exposed to these three risk factors, which correlates
508 with previous reports indicating that individuals with HPV-positive OPSCCs are more likely to
509 be never or former smokers, or drinkers [25, 57, 59, 89, 90]. Nonetheless, these are common risk
510 factors for HPV-positive OPSCC, and in Western countries, 10-30% of OPSCC tumors occur in
511 individuals that smoke or drink [27, 91]. In this study, we observed a transformation from cancer
512 that is derived from only smoking, betel quid, and alcohol influence, to an increasing trend of
513 HPV-positive cases. The strong association of HPV with better outcome has been widely
514 reported [23, 25, 27, 28, 35, 42, 44-50]. Our results, showing that HPV-positive OPSCCs have a
515 strikingly better prognosis, agree with these and previous work from South-East Asia and
516 Taiwan [57, 59]. Additional evidence showed that in our Taiwan cohort, even when having
517 poorer outcomes, drinkers, smokers, and betel quid users benefited from the simultaneous
518 presence of HPV, displaying higher OPSCC survival rates than those HPV-negative. Similar
519 interactions have been seen before, especially for smoking or tobacco use and HPV [27, 89].
520 These results may have a substantial impact on the clinical management of OPSCC patients in
521 Taiwan and their risk stratification. HPV-positive individuals could benefit from the secession of
522 alcohol, smoking, or betel quid habits and therapy de-escalation, as it is currently tested in
523 diverse hospital settings to reduce toxicity and post-treatment morbidity [13, 49, 50, 59, 92, 93].

524 To our knowledge, this is the first comprehensive study analyzing the impact of HPV-
525 driven OPSCC in Taiwan. Our approach of matching HPV status and prevalence data to clinical
526 features, risk behavior exposure, and clinical outcomes represents a distinctive strength of our
527 study, adding to our understanding of an under-represented ethnic group in Western
528 epidemiological studies. Also, double p16-HPV DNA testing provided clinical relevance to the
529 findings, as the concordance of the results was very high. Because p16 as a surrogate marker for

530 HPV-driven OPSCCs can account for more than 5% false positives [10, 94, 95], we did not rely
531 solely on this test and performed DNA testing for HPV. Our study also suffers from limitations.
532 Cases from a single center, the Chang Gung Memorial Hospital at Linkou, in Taiwan, were
533 included in the study. However, it is the first and largest cancer center in Taiwan, providing
534 cancer care to roughly a quarter of the country's cancer patients which is a reasonably valid
535 representation of the Taiwanese population. Although, limits to access were not assessed, which
536 could introduce bias. An additional limitation is represented by the lack of both p16 and HPV-
537 DNA results for all the specimens, as several were missing or had insufficient amount of tissue
538 available for analysis (see Fig 1, S1 Table). The retrospective nature of our study also presented
539 challenges to this work. We could not evaluate the impact of therapy because changes to
540 treatment strategies occurred over time, and we were unable to follow changes in sexual
541 behaviors that could perhaps help explain the occurrence of HPV in Taiwan. Data on risk factors
542 were limited, as we could not retrieve the exact amounts and type of alcohol, cigarettes, or betel
543 quid consumed, nor information on previous infections with hrHPV, or comorbidities. For the
544 same reason, disease specific survival times could not be calculated. The AJCC TNM staging
545 system changed to include HPV status in 2017 [96]; however, our cases were classified at
546 diagnosis following previous guidance, and staging changes were not reflected in the reported N-
547 status.

548 Future research should incorporate efforts to further characterize HPV-driven OPSCC in
549 Taiwan. Since our cohort included a limited number of females, future studies aiming at
550 clarifying the implication of this disease in women, who also suffer from HPV-driven cervical
551 and genital cancers, are needed. Importantly, studies related to the collection of specific
552 epidemiological data will be relevant to guide new public health policies. Since oral hrHPV

553 infections precede the development of OPSCC, research on the natural history of this disease,
554 including the prevalence of HPV genotypes, will help strengthen the current HPV vaccination
555 efforts. The HPV vaccine was recently introduced in Taiwan nationwide, targeting only
556 prepubescent girls. Still, our studies reflect that boys will also benefit from vaccination, as it has
557 the potential to halt the expansion of HPV-positive OPSCC and other cancers [40, 56, 59]. HPV
558 vaccination uptake is presumably low, and initially only the bivalent (HPV 16/18) and tetravalent
559 (HPV 6/11/16/18) vaccines were used. Our data indicate that in this Taiwanese population
560 HPV58 was the second most common hrHPV genotype. The nonavalent vaccine, which protects
561 against HPV58 and other 8 HPV genotypes (HPV 6/11/16/18/31/33/45/52/58), would be the
562 most appropriate choice for this target population based on our study. However, even that
563 vaccine (without assuming cross reactivity) would not cover HPV35, 31, 59, and 66, which we
564 found respectively account for 2.2%, 1.5%, 1.5%, and 1% each. New prospective studies have
565 the potential to shed light on the risk of OPSCC within the vaccinated population and have broad
566 public health implications for control measures. Lastly, multicenter, nationwide studies will
567 provide an understanding of the variables leading to HPV oncogenesis in this population,
568 improving risk definition, outcome prediction, and patient stratification. All these are necessary
569 to provide patients with appropriate care based on their HPV status. Additional investigations
570 into the molecular mechanism of HPV-induced OPSCC are also required to address the risk of
571 recurrence and progression in Taiwan. Based on risk evaluation, HPV-positive OPSCC patients
572 may be candidates for therapy de-intensification. Tailored interventions should also be designed
573 based on longitudinal investigations of the interaction between HPV and risk behaviors,
574 including drinking, smoking, and chewing betel quid.

575 In conclusion, our retrospective study provides empirical evidence on the impact of
576 hrHPV on OPSCCs in a large cohort from Taiwan. We found that HPV is present and likely an
577 increasing etiological factor in these Taiwanese individuals with OPSCC. These observations
578 may represent continuous behavioral changes in Taiwan. HPV positivity is associated with
579 significantly better outcomes. Involvement in risk habits, alcohol, cigarette, and betel quid use
580 was still widespread, but the substantial prognostic benefit of HPV remained present. Thus, this
581 consistent trend reflects the need for policies and sustained public health interventions aiming to
582 improve the management and prevention of HPV-driven OPSCC in Taiwan.

593

594 **Acknowledgments**

595 We would like to thank the patients who generously contributed to the study, and the members of
596 the Cancer Center, Chang Gung Memorial Hospital, for their invaluable help.

597

598 **References**

- 599 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
600 statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in
601 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
- 602 2. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control
603 study of human papillomavirus and oropharyngeal cancer. *N Engl J Med.* 2007;356(19):1944-56.
- 604 3. Elrefaey S, Massaro MA, Chiocca S, Chiesa F, Ansarin M. HPV in oropharyngeal
605 cancer: the basics to know in clinical practice. *Acta Otorhinolaryngol Ital.* 2014;34(5):299-309.
- 606 4. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in
607 the U.S. population ages 20-44 years. *Cancer.* 2005;103(9):1843-9.
- 608 5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. *CA Cancer J Clin.* 2019;69(1):7-
609 34.
- 610 6. Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, et al.
611 Smoking and drinking in relation to oral and pharyngeal cancer. *Cancer Res.* 1988;48(11):3282-
612 7.

- 613 7. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. Meta-analysis of the impact
614 of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous
615 cell carcinomas (HNSCC). *Head Neck Oncol.* 2010;2:15.
- 616 8. Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, et al. Interaction
617 between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the
618 International Head and Neck Cancer Epidemiology Consortium. *Cancer Epidemiol Biomarkers*
619 *Prev.* 2009;18(2):541-50.
- 620 9. Ho PS, Ko YC, Yang YH, Shieh TY, Tsai CC. The incidence of oropharyngeal cancer in
621 Taiwan: an endemic betel quid chewing area. *J Oral Pathol Med.* 2002;31(4):213-9.
- 622 10. Nauta IH, Rietbergen MM, van Bokhoven AAJD, Bloemena E, Lissenberg-Witte BI,
623 Heideman DAM, et al. Evaluation of the eighth TNM classification on p16-positive
624 oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional
625 HPV DNA testing. *Ann Oncol.* 2018;29(5):1273-9.
- 626 11. Sturgis EM, Ang KK. The epidemic of HPV-associated oropharyngeal cancer is here: is
627 it time to change our treatment paradigms? *J Natl Compr Canc Netw.* 2011;9(6):665-73.
- 628 12. Talamini R, Vaccarella S, Barbone F, Tavani A, La Vecchia C, Herrero R, et al. Oral
629 hygiene, dentition, sexual habits and risk of oral cancer. *Br J Cancer.* 2000;83(9):1238-42.
- 630 13. Westra WH. The morphologic profile of HPV-related head and neck squamous
631 carcinoma: implications for diagnosis, prognosis, and clinical management. *Head Neck Pathol.*
632 2012;6 Suppl 1:S48-54.
- 633 14. Znaor A, Brennan P, Gajalakshmi V, Mathew A, Shanta V, Varghese C, et al.
634 Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk
635 of oral, pharyngeal and esophageal cancers in Indian men. *Int J Cancer.* 2003;105(5):681-6.
- 636 15. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, World
637 Health Organization., International Agency for Research on Cancer. Betel-quid and areca-nut
638 chewing and some areca-nut-derived nitrosamines. Lyon, France
639 Geneva: IARC Press ;
640 Distributed by IARC Press and the World Health Organization Marketing and Dissemination;
641 2004. x, 334 p. p.
- 642 16. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., International
643 Agency for Research on Cancer., National Cancer Institute (U.S.). Alcohol drinking. Lyon,
644 France: World Health Organization, International Agency for Research on Cancer; 1988. 416 p.
645 p.
- 646 17. IARC Working Group on the Evaluation of the Carcinogenic Risk of Chemicals to
647 Humans, International Agency for Research on Cancer. Tobacco habits other than smoking,
648 betel-quid and areca-nut chewing, and some related nitrosamines. Lyon, France: International
649 Agency for Research on Cancer; 1985. 291 pages, 4 pages of plates p.
- 650 18. Ng M, Freeman MK, Fleming TD, Robinson M, Dwyer-Lindgren L, Thomson B, et al.
651 Smoking prevalence and cigarette consumption in 187 countries, 1980-2012. *JAMA.*
652 2014;311(2):183-92.
- 653 19. Zumsteg ZS, Cook-Wiens G, Yoshida E, Shiao SL, Lee NY, Mita A, et al. Incidence of
654 Oropharyngeal Cancer Among Elderly Patients in the United States. *JAMA Oncol.*
655 2016;2(12):1617-23.

- 656 20. Allen CT, Lewis JS, El-Mofty SK, Haughey BH, Nussenbaum B. Human papillomavirus
657 and oropharynx cancer: biology, detection and clinical implications. *Laryngoscope*.
658 2010;120(9):1756-72.
- 659 21. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck
660 cancers. *J Clin Oncol*. 2006;24(17):2606-11.
- 661 22. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for
662 a causal association between human papillomavirus and a subset of head and neck cancers. *J Natl*
663 *Cancer Inst*. 2000;92(9):709-20.
- 664 23. Gillison ML, D'Souza G, Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk
665 factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-
666 negative head and neck cancers. *J Natl Cancer Inst*. 2008;100(6):407-20.
- 667 24. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human
668 Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin Oncol*.
669 2015;33(29):3235-42.
- 670 25. Kumar B, Cordell KG, Lee JS, Worden FP, Prince ME, Tran HH, et al. EGFR, p16, HPV
671 Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in
672 oropharyngeal cancer. *J Clin Oncol*. 2008;26(19):3128-37.
- 673 26. Licitra L, Bossi P, Locati LD. A multidisciplinary approach to squamous cell carcinomas
674 of the head and neck: what is new? *Curr Opin Oncol*. 2006;18(3):253-7.
- 675 27. Maxwell JH, Kumar B, Feng FY, Worden FP, Lee JS, Eisbruch A, et al. Tobacco use in
676 human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of
677 distant metastases and tumor recurrence. *Clin Cancer Res*. 2010;16(4):1226-35.
- 678 28. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, et al. Chemoselection
679 as a strategy for organ preservation in advanced oropharynx cancer: response and survival
680 positively associated with HPV16 copy number. *J Clin Oncol*. 2008;26(19):3138-46.
- 681 29. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans., International
682 Agency for Research on Cancer. Human papillomaviruses. Lyon, France
683 Geneva, Switzerland: World Health Organization
684 Distributed by WHO Press; 2007. viii, 670 p. p.
- 685 30. Begum S, Cao D, Gillison M, Zahurak M, Westra WH. Tissue distribution of human
686 papillomavirus 16 DNA integration in patients with tonsillar carcinoma. *Clin Cancer Res*.
687 2005;11(16):5694-9.
- 688 31. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of
689 human carcinogens--Part B: biological agents. *Lancet Oncol*. 2009;10(4):321-2.
- 690 32. Mork J, Lie AK, Glatte E, Hallmans G, Jellum E, Koskela P, et al. Human
691 papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. *N*
692 *Engl J Med*. 2001;344(15):1125-31.
- 693 33. Rampias T, Sasaki C, Weinberger P, Psyrris A. E6 and e7 gene silencing and transformed
694 phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. *J Natl Cancer Inst*.
695 2009;101(6):412-23.
- 696 34. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The
697 mutational landscape of head and neck squamous cell carcinoma. *Science*.
698 2011;333(6046):1157-60.

- 699 35. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human
700 papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. *J Clin*
701 *Oncol.* 2008;26(4):612-9.
- 702 36. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human
703 papillomavirus and rising oropharyngeal cancer incidence in the United States. *J Clin Oncol.*
704 2011;29(32):4294-301.
- 705 37. Ernster JA, Sciotto CG, O'Brien MM, Finch JL, Robinson LJ, Willson T, et al. Rising
706 incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus.
707 *Laryngoscope.* 2007;117(12):2115-28.
- 708 38. Stein AP, Saha S, Yu M, Kimple RJ, Lambert PF. Prevalence of human papillomavirus in
709 oropharyngeal squamous cell carcinoma in the United States across time. *Chem Res Toxicol.*
710 2014;27(4):462-9.
- 711 39. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et
712 al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol.*
713 2013;31(36):4550-9.
- 714 40. Gooi Z, Chan JY, Fakhry C. The epidemiology of the human papillomavirus related to
715 oropharyngeal head and neck cancer. *Laryngoscope.* 2016;126(4):894-900.
- 716 41. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, et
717 al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. *Int J*
718 *Cancer.* 2006;119(11):2620-3.
- 719 42. Boscolo-Rizzo P, Pawlita M, Holzinger D. From HPV-positive towards HPV-driven
720 oropharyngeal squamous cell carcinomas. *Cancer Treat Rev.* 2016;42:24-9.
- 721 43. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L, et al. Prognoses
722 and improvement for head and neck cancers diagnosed in Europe in early 2000s: The
723 EUROCORE-5 population-based study. *Eur J Cancer.* 2015;51(15):2130-43.
- 724 44. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human
725 papillomavirus and survival of patients with oropharyngeal cancer. *N Engl J Med.*
726 2010;363(1):24-35.
- 727 45. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of
728 patients with human papillomavirus-positive head and neck squamous cell carcinoma in a
729 prospective clinical trial. *J Natl Cancer Inst.* 2008;100(4):261-9.
- 730 46. Fakhry C, Westra WH, Wang SJ, van Zante A, Zhang Y, Rettig E, et al. The prognostic
731 role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and
732 neck squamous cell cancer. *Cancer.* 2017;123(9):1566-75.
- 733 47. Haughey BH, Hinni ML, Salassa JR, Hayden RE, Grant DG, Rich JT, et al. Transoral
734 laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United
735 States multicenter study. *Head Neck.* 2011;33(12):1683-94.
- 736 48. Horne ZD, Glaser SM, Vargo JA, Ferris RL, Balasubramani GK, Clump DA, et al.
737 Confirmation of proposed human papillomavirus risk-adapted staging according to AJCC/UICC
738 TNM criteria for positive oropharyngeal carcinomas. *Cancer.* 2016;122(13):2021-30.
- 739 49. Quon H, Cohen MA, Montone KT, Ziober AF, Wang LP, Weinstein GS, et al. Transoral
740 robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16
741 INK4a on treatment outcomes. *Laryngoscope.* 2013;123(3):635-40.
- 742 50. Rietbergen MM, Brakenhoff RH, Bloemena E, Witte BI, Snijders PJ, Heideman DA, et
743 al. Human papillomavirus detection and comorbidity: critical issues in selection of patients with
744 oropharyngeal cancer for treatment De-escalation trials. *Ann Oncol.* 2013;24(11):2740-5.

- 745 51. Chuang SL, Su WW, Chen SL, Yen AM, Wang CP, Fann JC, et al. Population-based
746 screening program for reducing oral cancer mortality in 2,334,299 Taiwanese cigarette smokers
747 and/or betel quid chewers. *Cancer*. 2017;123(9):1597-609.
- 748 52. Hsu KY, Tsai YF, Huang CC, Yeh WL, Chang KP, Lin CC, et al. Tobacco-Smoking,
749 Alcohol-Drinking, and Betel-Quid-Chewing Behaviors: Development and Use of a Web-Based
750 Survey System. *JMIR Mhealth Uhealth*. 2018;6(6):e142.
- 751 53. Lee YA, Li S, Chen Y, Li Q, Chen CJ, Hsu WL, et al. Tobacco smoking, alcohol
752 drinking, betel quid chewing, and the risk of head and neck cancer in an East Asian population.
753 *Head Neck*. 2019;41(1):92-102.
- 754 54. Shiu MN, Chen TH. Impact of betel quid, tobacco and alcohol on three-stage disease
755 natural history of oral leukoplakia and cancer: implication for prevention of oral cancer. *Eur J*
756 *Cancer Prev*. 2004;13(1):39-45.
- 757 55. Hwang TZ, Hsiao JR, Tsai CR, Chang JS. Incidence trends of human papillomavirus-
758 related head and neck cancer in Taiwan, 1995-2009. *Int J Cancer*. 2015;137(2):395-408.
- 759 56. Wang CP, Chen TC, Chen HH, Hsu WL, Chang YL. Prevalence of current oral HPV
760 infection among 100 betel nut chewers or cigarette smokers in Northern Taiwan. *J Formos Med*
761 *Assoc*. 2019;118(1 Pt 1):203-8.
- 762 57. Chien CY, Su CY, Fang FM, Huang HY, Chuang HC, Chen CM, et al. Lower prevalence
763 but favorable survival for human papillomavirus-related squamous cell carcinoma of tonsil in
764 Taiwan. *Oral Oncol*. 2008;44(2):174-9.
- 765 58. Huang H, Zhang B, Chen W, Zou SM, Zhang YX, Qiao YL. [Detection of human
766 papillomavirus in oropharyngeal squamous cell carcinoma]. *Zhongguo Yi Xue Ke Xue Yuan*
767 *Xue Bao*. 2012;34(6):545-9.
- 768 59. Lam EW, Chan JY, Chan AB, Ng CS, Lo ST, Lam VS, et al. Prevalence,
769 Clinicopathological Characteristics, and Outcome of Human Papillomavirus-Associated
770 Oropharyngeal Cancer in Southern Chinese Patients. *Cancer Epidemiol Biomarkers Prev*.
771 2016;25(1):165-73.
- 772 60. Li W, Tran N, Lee SC, O'Brien CJ, Tse GM, Scolyer RA, et al. New evidence for
773 geographic variation in the role of human papillomavirus in tonsillar carcinogenesis. *Pathology*.
774 2007;39(2):217-22.
- 775 61. Maruyama H, Yasui T, Ishikawa-Fujiwara T, Morii E, Yamamoto Y, Yoshii T, et al.
776 Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among
777 Japanese population. *Cancer Sci*. 2014;105(4):409-17.
- 778 62. No JH, Sung MW, Hah JH, Choi SH, Lee MC, Kim HS, et al. Prevalence and prognostic
779 value of human papillomavirus genotypes in tonsillar squamous cell carcinoma: a Korean
780 multicenter study. *Cancer*. 2015;121(4):535-44.
- 781 63. Ko YC, Chiang TA, Chang SJ, Hsieh SF. Prevalence of betel quid chewing habit in
782 Taiwan and related sociodemographic factors. *J Oral Pathol Med*. 1992;21(6):261-4.
- 783 64. Edge SB, American Joint Committee on Cancer., American Cancer Society. *AJCC*
784 *cancer staging handbook : from the AJCC cancer staging manual*. 7th ed. New York: Springer;
785 2010. xix, 718 p. p.
- 786 65. Walline HM, Komarck C, McHugh JB, Byrd SA, Spector ME, Hauff SJ, et al. High-risk
787 human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers:
788 comparison of multiple methods. *JAMA Otolaryngol Head Neck Surg*. 2013;139(12):1320-7.

- 789 66. Walline HM, Carey TE, Goudsmit CM, Bellile EL, D'Souza G, Peterson LA, et al. High-
790 Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients
791 Positive and Negative for HIV. *Mol Cancer Res.* 2017;15(2):179-88.
- 792 67. Walline HM, Goudsmit CM, McHugh JB, Tang AL, Owen JH, Teh BT, et al. Integration
793 of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell
794 lines. *Head Neck.* 2017;39(5):840-52.
- 795 68. Lewis JS, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human
796 Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American
797 Pathologists. *Arch Pathol Lab Med.* 2018;142(5):559-97.
- 798 69. Moore EJ, Olsen SM, Laborde RR, García JJ, Walsh FJ, Price DL, et al. Long-term
799 functional and oncologic results of transoral robotic surgery for oropharyngeal squamous cell
800 carcinoma. *Mayo Clin Proc.* 2012;87(3):219-25.
- 801 70. Yeh DH, Tam S, Fung K, MacNeil SD, Yoo J, Winkquist E, et al. Transoral robotic
802 surgery vs. radiotherapy for management of oropharyngeal squamous cell carcinoma - A
803 systematic review of the literature. *Eur J Surg Oncol.* 2015;41(12):1603-14.
- 804 71. Li W, Thompson CH, O'Brien CJ, McNeil EB, Scolyer RA, Cossart YE, et al. Human
805 papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. *Int*
806 *J Cancer.* 2003;106(4):553-8.
- 807 72. Ndiaye C, Mena M, Alemany L, Arbyn M, Castellsagué X, Laporte L, et al. HPV DNA,
808 E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-
809 analysis. *Lancet Oncol.* 2014;15(12):1319-31.
- 810 73. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head
811 and neck squamous cell carcinomas worldwide: a systematic review. *Cancer Epidemiol*
812 *Biomarkers Prev.* 2005;14(2):467-75.
- 813 74. Amit M, Ilana K, Avraham SP, Binenbaum Y, Bachar G, Billan S, et al. Trends in human
814 papillomavirus-related oropharyngeal cancer in Israel. *Head Neck.* 2016;38 Suppl 1:E274-8.
- 815 75. Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, et al. Human
816 papillomavirus infection in Shanxi Province, People's Republic of China: a population-based
817 study. *Br J Cancer.* 2006;95(1):96-101.
- 818 76. Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, et al. Human papillomavirus
819 infection in Shenyang City, People's Republic of China: A population-based study. *Br J Cancer.*
820 *2006;95(11):1593-7.*
- 821 77. Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, et al. Human papillomavirus
822 infection in women in Shenzhen City, People's Republic of China, a population typical of recent
823 Chinese urbanisation. *Int J Cancer.* 2007;121(6):1306-11.
- 824 78. Lin H, Ma YY, Moh JS, Ou YC, Shen SY, ChangChien CC. High prevalence of genital
825 human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in
826 South Taiwan. *Gynecol Oncol.* 2006;101(1):40-5.
- 827 79. Lai CH, Huang HJ, Hsueh S, Chao A, Lin CT, Huang SL, et al. Human papillomavirus
828 genotype in cervical cancer: a population-based study. *Int J Cancer.* 2007;120(9):1999-2006.
- 829 80. Chen HC, You SL, Hsieh CY, Schiffman M, Lin CY, Pan MH, et al. Prevalence of
830 genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: a
831 community-based survey of 10,602 women. *Int J Cancer.* 2011;128(5):1192-203.
- 832 81. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human
833 papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a
834 meta-analysis update. *Int J Cancer.* 2007;121(3):621-32.

- 835 82. Jeng CJ, Phdl, Ko ML, Ling QD, Shen J, Lin HW, et al. Prevalence of cervical human
836 papillomavirus in Taiwanese women. *Clin Invest Med*. 2005;28(5):261-6.
- 837 83. Wang CH, Garvilles RG, Chen CY. Characterization of human papillomavirus infection
838 in north Taiwan. *J Med Virol*. 2010;82(8):1416-23.
- 839 84. Chan PK, Cheung TH, Li WH, Yu MY, Chan MY, Yim SF, et al. Attribution of human
840 papillomavirus types to cervical intraepithelial neoplasia and invasive cancers in Southern China.
841 *Int J Cancer*. 2012;131(3):692-705.
- 842 85. Chan PK, Ho WC, Chan MC, Wong MC, Yeung AC, Chor JS, et al. Meta-analysis on
843 prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia
844 worldwide. *PLoS One*. 2014;9(9):e107573.
- 845 86. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus
846 infection. *Best Pract Res Clin Obstet Gynaecol*. 2018;47:2-13.
- 847 87. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of
848 oral HPV infection in the United States, 2009-2010. *JAMA*. 2012;307(7):693-703.
- 849 88. Steinau M, Saraiya M, Goodman MT, Peters ES, Watson M, Cleveland JL, et al. Human
850 papillomavirus prevalence in oropharyngeal cancer before vaccine introduction, United States.
851 *Emerg Infect Dis*. 2014;20(5):822-8.
- 852 89. Vawda N, Banerjee RN, Debenham BJ. Impact of Smoking on Outcomes of HPV-related
853 Oropharyngeal Cancer Treated with Primary Radiation or Surgery. *Int J Radiat Oncol Biol Phys*.
854 2019;103(5):1125-31.
- 855 90. Morbini P, Alberizzi P, Ferrario G, Capello G, De Silvestri A, Pedrazzoli P, et al. The
856 evolving landscape of human papillomavirus-related oropharyngeal squamous cell carcinoma at
857 a single institution in Northern Italy. *Acta Otorhinolaryngol Ital*. 2019;39(1):9-17.
- 858 91. Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP. Complex etiology
859 underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol:
860 a case for multifactor disease. *J Oncol*. 2012;2012:571862.
- 861 92. Münger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al.
862 Mechanisms of human papillomavirus-induced oncogenesis. *J Virol*. 2004;78(21):11451-60.
- 863 93. Parfenov M, Pedamallu CS, Gehlenborg N, Freeman SS, Danilova L, Bristow CA, et al.
864 Characterization of HPV and host genome interactions in primary head and neck cancers. *Proc
865 Natl Acad Sci U S A*. 2014;111(43):15544-9.
- 866 94. Bussu F, Sali M, Gallus R, Vellone VG, Zannoni GF, Autorino R, et al. HPV infection in
867 squamous cell carcinomas arising from different mucosal sites of the head and neck region. Is
868 p16 immunohistochemistry a reliable surrogate marker? *Br J Cancer*. 2013;108(5):1157-62.
- 869 95. Rietbergen MM, Snijders PJ, Beekzada D, Braakhuis BJ, Brink A, Heideman DA, et al.
870 Molecular characterization of p16-immunopositive but HPV DNA-negative oropharyngeal
871 carcinomas. *Int J Cancer*. 2014;134(10):2366-72.
- 872 96. Amin MB, Edge SB, American Joint Committee on Cancer. *AJCC cancer staging
873 manual*. Eighth edition. ed. Switzerland: Springer; 2017. xvii, 1024 pages p.

874

875 **Supporting information**

876 **S1 Checklist. Strengthening the Reporting of Observational Studies in Epidemiology**
877 **(STROBE) report.**

878

879 **S1 Fig. Representative p16 immunostaining for OPSCC tissue sections.** Specimens from
880 example p16-negative (P0283) and p16-positive (P0267) tumors are displayed. p16 expression is
881 observed as a brown nuclear and cytoplasmic coloration. Magnification, 200x.

882

883 **S2 Fig. Kaplan-Meier plots for survival outcomes by gender.** Up to 5-year overall survival
884 (OS) and disease-free survival (DFS) outcomes were analyzed within the whole cohort by the
885 Kaplan-Meier method and log-rank test (*p*-values).

886

887 **S3 Fig. Kaplan-Meier plots for survival outcomes by alcohol, smoking, and betel quid.** (A-
888 C) Comparison of prognostic outcomes of (A) alcohol, (B) smoke, and (C) betel quid between
889 the whole cohort and HPV risk groups. HPV positivity is defined as HPV DNA-positive and/or
890 p16-positive. Up to 5-year overall survival (OS, top) and disease-free survival (DFS, bottom)
891 probabilities were analyzed by the Kaplan-Meier method and log-rank test (*p*-values), as
892 displayed for each risk group. HPV-, HPV-negative; HPV+, HPV-positive.

893

894 **S4 Fig. HPV-positive OPSCC is associated with increased disease-free survival time in the**
895 **presence of other risk factors.** (A-C) Up to 5-year disease-free survival (DFS) prognostic
896 outcome of the HPV variable within alcohol, and smoking and/or betel quid risk groups. HPV
897 positivity is defined as HPV DNA-positive and/or p16-positive. The DFS smoking and betel quid

898 variables were not analyzed individually due to low number of events. (A) Table includes the
899 multivariable hazard probabilities analyzed using Cox survival models and hazard ratio (HR)
900 estimations, adjusted for age, T- and N-stage, and which were visualized by forest plots. The
901 complete analysis is found in S8 Table. (B-C) Kaplan-Meier survival analysis. Plots represent
902 the DFS probabilities of cases stratified by HPV status within the (B) alcohol and (C) smoke
903 and/or betel quid groups. Left, plots showing cases with alcohol or smoke and/or betel quid
904 consumption. Right, plots showing cases without exposition to alcohol or smoke and/or betel
905 quid. Log-rank analysis was used to compare the survival distributions (log-rank p -values are in
906 the plots). HPV-, HPV-negative; HPV+, HPV-positive.

907

908 **S1 Table. HPV status and patient data.**

909

910 **S2 Table. p16 vs. HPV DNA results.**

911

912 **S3 Table. Yearly HPV occurrence.**

913

914 **S4 Table. Risk factors exposure characteristics, and differences regarding HPV status.**

915

916 **S5 Table. Clinical and demographic characteristics by gender.**

917

918 **S6 Table. Multivariable survival analysis of the whole cohort.**

919

920 **S7 Table. Multivariable survival analysis for alcohol, smoking, and quid within HPV risk**
921 **groups, adjusted for age, T- and N-stage.**

922

923 **S8 Table. Multivariable disease-free survival analysis by HPV within alcohol, and smoking**
924 **and/or betel quid risk groups (controlled for alcohol, and smoking and/or betel quid). All**
925 **models control for age, T- and N-stage.**

926

927 **Author Contributions**

928 **Conceptualization:** Thomas E. Carey, Kai-Ping Chang, Heather M. Walline, Guadalupe
929 Lorenzatti Hiles, Emily L. Bellile.

930 **Data Curation:** Guadalupe Lorenzatti Hiles, Emily L. Bellile, Chun-I Wang, Wei-Chen Yen,
931 Lisa M. Pinatti, Heather M. Walline.

932 **Formal Analysis:** Guadalupe Lorenzatti Hiles, Emily L. Bellile, Heather M. Walline.

933 **Funding Acquisition:** Guadalupe Lorenzatti Hiles, Kai-Ping Chang, Thomas E. Carey, Heather
934 M. Walline.

935 **Investigation:** Guadalupe Lorenzatti Hiles, Chun-I Wang, Wei-Chen Yen, Christine M.
936 Goudsmit, Hannah L. Briggs, Trey B. Thomas, Lila Peters, Macy A. Afsari, Anna C. Morris,
937 Nadine Jawad, Heather M. Walline.

938 **Project Administration:** Thomas E. Carey, Kai-Ping Chang, Heather M. Walline, Guadalupe
939 Lorenzatti Hiles, Christine M. Goudsmit.

940 **Resources:** Kai-Ping Chang, Thomas E. Carey, Heather M. Walline.

941 **Supervision:** Kai-Ping Chang, Thomas E. Carey, Heather M. Walline.

942 **Validation:** Guadalupe Lorenzatti Hiles, Emily L. Bellile, Hannah L. Briggs, Macy A. Afsari,
943 Heather M. Walline.

944 **Visualization:** Guadalupe Lorenzatti Hiles, Emily L. Bellile, Macy A. Afsari.

945 **Writing – Original Draft Preparation:** Guadalupe Lorenzatti Hiles.

946 **Writing – Review & Editing:** Guadalupe Lorenzatti Hiles, Kai-Ping Chang, Emily L. Bellile,
947 Chun-I Wang, Wei-Chen Yen, Christine M. Goudsmit, Hannah L. Briggs, Trey B. Thomas, Lila
948 Peters, Macy A. Afsari, Lisa M. Pinatti, Anna C. Morris, Nadine Jawad, Thomas E. Carey,
949 Heather M. Walline.

950

951 **Data Availability Statement:** All relevant data needed to reproduce our findings are included in
952 this manuscript and its Supporting Information, excepting sensitive dates that could allow the
953 identification of the patients in this study.

954


955 **Funding:** This study was funded by the University of Michigan-Chang Gung Memorial Hospital
956 Pilot Grant (<https://www.rogelcancercenter.org> and <https://www.cgmh.org.tw/en>) to K-PC and
957 TEC; the National Cancer Institute at the National Institutes of Health (<https://www.cancer.gov>),
958 CA194536 to TEC and HMW, and CA194536-S1 to GLH; the Chang Gung Memorial Hospital,
959 CMRPG3H0852, CMRPG3J1251, and CORPG3G0171 to K-PC; the Taiwan Ministry of
960 Science and Technology (<https://www.most.gov.tw>), MOST 108-2314-B-182A-108-MY3 to K-
961 PC; and, funds from the University of Michigan Undergraduate Research Opportunity Program
962 (<https://lsa.umich.edu/urop>) to GLH, TEC and HMW. The funders had no role in study design,
963 data collection and analysis, decision to publish, or preparation of the manuscript.


964

965 **Competing interests:** The authors have declared that no competing interests exist.

966

967 **Abbreviations:** CGMH, Chang Gung Memorial Hospital; DFS, disease-free survival;
968 EQUATOR, Enhancing the QUALity and Transparency Of health Research Network; FFPE,
969 formalin-fixed, paraffin-embedded; HPV, human papillomavirus; hrHPV, high-risk human
970 papillomavirus; IHC, immunohistochemical staining; OS, overall survival; OPSCC,
971 oropharyngeal squamous cell carcinoma; PCR-MA, multiplex PCR-MassArray; STROBE,
972 Strengthening the Reporting of Observational Studies in Epidemiology.



A**B**